Patent: 7,829,534
✉ Email this page to a colleague
Summary for Patent: 7,829,534
Title: | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
Abstract: | The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg. |
Inventor(s): | Larsen; Christian P. (Atlanta, GA), Pearson; Thomas C. (Atlanta, GA), Adams; Andrew B. (Atlanta, GA), Peach; Robert J. (San Diego, CA), Linsley; Peter S. (Seattle, WA), Naemura; Joseph Roy (Bellevue, WA), Bajorath; Jurgen (Bonn, DE) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/978,701 |
Patent Claims: | see list of patent claims |
Details for Patent 7,829,534
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2021-05-23 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2021-05-23 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2021-05-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |